Shares of Insmed Incorporated (NASDAQ:INSM) have received an average recommendation of “Buy” from the ten ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $36.71.
INSM has been the topic of several recent research reports. Leerink Swann upped their price objective on shares of Insmed from $27.00 to $36.00 and gave the company an “outperform” rating in a report on Tuesday, September 5th. BidaskClub downgraded shares of Insmed from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Zacks Investment Research downgraded shares of Insmed from a “buy” rating to a “hold” rating in a report on Monday, July 17th. ValuEngine downgraded shares of Insmed from a “hold” rating to a “sell” rating in a report on Thursday, August 3rd. Finally, HC Wainwright reiterated a “buy” rating on shares of Insmed in a research note on Wednesday, August 2nd.
Insmed (INSM) opened at 28.48 on Wednesday. The company’s market capitalization is $1.78 billion. Insmed has a 52-week low of $10.21 and a 52-week high of $31.39. The firm has a 50-day moving average of $17.85 and a 200 day moving average of $17.15.
Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.09). Equities analysts predict that Insmed will post ($2.70) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Insmed Incorporated (INSM) Receives Average Rating of “Buy” from Analysts” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://ledgergazette.com/2017/09/20/insmed-incorporated-insm-receives-average-rating-of-buy-from-analysts.html.
In other Insmed news, Director Donald J. Hayden, Jr. sold 45,000 shares of the company’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $29.67, for a total transaction of $1,335,150.00. Following the completion of the transaction, the director now directly owns 71,131 shares in the company, valued at $2,110,456.77. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Melvin Md Sharoky sold 50,000 shares of the company’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $27.37, for a total transaction of $1,368,500.00. The disclosure for this sale can be found here. Corporate insiders own 5.10% of the company’s stock.
A number of large investors have recently bought and sold shares of INSM. SG Americas Securities LLC purchased a new stake in shares of Insmed during the second quarter worth $129,000. BNP Paribas Arbitrage SA grew its holdings in shares of Insmed by 666.7% during the second quarter. BNP Paribas Arbitrage SA now owns 7,498 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 6,520 shares in the last quarter. UBS Asset Management Americas Inc. purchased a new stake in shares of Insmed during the second quarter worth $187,000. Driehaus Capital Management LLC purchased a new stake in shares of Insmed during the first quarter worth $192,000. Finally, Virtu KCG Holdings LLC purchased a new stake in shares of Insmed during the second quarter worth $201,000. Institutional investors own 73.08% of the company’s stock.
Insmed Company Profile
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Receive News & Ratings for Insmed Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.